Press Room

DCAT Week 2026

Start
Monday, March 23, 2026
End
Thursday, March 26, 2026
Location: New York, United States

Hovione is excited to be once again attending the DCAT Week, the premier global event held annually in New York City for companies engaged in the Bio/Pharmaceutical Manufacturing Value Chain.

Meet the Hovione team. This is the perfect opportunity to speak with our experts and learn how we are supporting our customers worldwide in developing novel drugs that make a difference for patients. Get to know more about:

  • Our One-Site Solution

    Hovione can deliver your entire project from one site, giving you the benefit of compressed timelines, seamless project management and knowledge, and increased sustainability.

     
  • Our Leadership in Spray Drying

    With the largest number of commercial projects, the best science and engineering, the largest capacity, and the most experienced team, Hovione can take your project from development to market like no one else.

     
  • Our Continuous Tableting Expertise

    For those aiming to go from development to manufacturing in record time with high quality and less variability, Hovione is Bridging Science and Manufacturing, allowing your drug product to be made faster and more efficiently today! Hovione can support Continuous Tableting based programs, including new products as well as batch to continuous conversions.

     
  • Our Innovative Platforms

    At Hovione we have a reputation for transforming nascent technologies into large-scale GMP-compliant platforms by building strategic partnerships with our customers and technology partners. We look forward to seeing you to share some exciting news.

 

Schedule a meeting today.

schedule a meeting

 

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026